 Connection
Margaret Macy to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications Margaret Macy has written about Antineoplastic Agents, Immunological.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.323 |
|
|
|
-
DuBois SG, Moreno L, Bagatell R, Cheung NK, Gray JC, Locatelli F, Reynolds CP, Rossig C, Sondel PM, Drezner N, Kholmanshikh O, Bird N, Day L, Ludwinski D, Scobie N, Pons Sanz V, Ball S, Hammer B, Alvarez Rojo I, Meager D, Sveistrup J, Berlanga P, Casanova M, Glade-Bender J, Macy M, Morgenstern DA, Owens C, Weigel BJ, Pappo A, Nysom K, Anderson J, Ligas F, Lesa G, Donoghue M, Karres D, Vassal G. Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer. Eur J Cancer. 2025 Dec 09; 231:116093.
Score: 0.194
-
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020 01; 21(1):121-133.
Score: 0.129
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|